Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
B Cells in Pregnancy: Functional Promiscuity or Tailored Function?
Navigating Life and Loss in Pediatric Multiple Sclerosis.
[Cost of multiple sclerosis in France.]
Molecular cloning of a human cannabinoid receptor which is also expressed in testis.
[CHANGES IN THE QUALITATIVE AND QUANTITATIVE COMPOSITION OF GUT MICROBIOTA IN RATS DURING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS].
Fingolimod (Gilenya) licence extended
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Excitotoxic mechanisms of ischemic injury in myelinated white matter.
ER Chaperone BiP/GRP78 Is Required for Myelinating Cell Survival and Provides Protection during Experimental Autoimmune Encephalomyelitis.
Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.
Multiple sclerosis, solitary sclerosis or something else?
Feedforward postural control in individuals with multiple sclerosis during load release.
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Natalizumab in spinal multiple sclerosis in a daily clinical setting.
[Oral disease modifying therapy of multiple sclerosis: the current view.]
NMO spectrum presenting as partial myelitis.
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).
Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation.
[The role of chronic venous insufficiency in the pathogenesis of brain diseases].
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
Alemtuzumab Therapy for Multiple Sclerosis.
The long-term cost-effectiveness of the use of Functional Electrical Stimulation for the correction of dropped foot due to upper motor neuron lesion.
25-Hydroxycholecalciferol status in plasma is linearly correlated to daily summer pasture time in cattle at 56°N.
Alemtuzumab: The advantages and challenges of a novel therapy in MS.
[Magnetic reasonance spectroscopy-guided stereotactic biopsy for brain lesion].
Pages
« first
‹ previous
…
185
186
187
188
189
190
191
192
193
…
next ›
last »